A psychometric evaluation of the Hospital Anxiety and Depression Scale in patients diagnosed with end-stage renal disease

Objectives: To determine the psychometric properties of the Hospital Anxiety and Depression Scale (HADS) in patients with end‐stage renal disease (ESRD) and determine the suitability of the instrument for use with this clinical group. Design: Between‐subjects and cross‐sectional design. The independ...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical psychology Vol. 43; no. 1; pp. 51 - 64
Main Authors Martin, Colin R., Tweed, Alison E., Metcalfe, Matthew S.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.03.2004
British Psychological Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objectives: To determine the psychometric properties of the Hospital Anxiety and Depression Scale (HADS) in patients with end‐stage renal disease (ESRD) and determine the suitability of the instrument for use with this clinical group. Design: Between‐subjects and cross‐sectional design. The independent variable was type of treatment for ESRD. The dependent variables were HADS total (all items) and HADS anxiety and depression subscale scores. Methods: Group differences in HADS scores were determined using between‐subjects one‐way analysis of variance (ANOVA). Exploratory and confirmatory factor analyses were conducted on the HADS to determine its psychometric properties in 160 patients with ESRD. Seven models were tested to determine model fit to the data. Results: None of the seven models tested proved to be an adequate fit to the data. Treatment modality was found to have a significant impact on HADS‐assessed levels of anxiety and depression. Conclusions: The clinical utility of the HADS in the assessment of anxiety and depression in ESRD patients may be enhanced by using the HADS total (all items) score as an index of psychological distress. Further research is required to establish the appropriateness of using the HADS to screen ESRD patients.
Bibliography:ark:/67375/WNG-DRHNP989-D
ArticleID:BJC181
istex:887E5F5244D65465C77F0D44C3C71B4B587FCAED
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Feature-3
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Undefined-3
ISSN:0144-6657
2044-8260
DOI:10.1348/014466504772812968